Evolus (NASDAQ:EOLS – Get Free Report) will likely be issuing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $81.5480 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.
Evolus (NASDAQ:EOLS – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The company had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same quarter last year, the business posted ($0.30) EPS. On average, analysts expect Evolus to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Evolus Price Performance
Shares of Evolus stock opened at $5.84 on Monday. Evolus has a 1 year low of $3.86 and a 1 year high of $9.35. The firm has a market cap of $384.62 million, a PE ratio of -8.72 and a beta of 1.35. The company has a 50 day simple moving average of $6.47 and a two-hundred day simple moving average of $5.49.
Analysts Set New Price Targets
Read Our Latest Research Report on Evolus
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Rhumbline Advisers lifted its holdings in shares of Evolus by 2.0% in the 2nd quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock worth $784,000 after acquiring an additional 1,657 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after purchasing an additional 1,838 shares during the period. Invesco Ltd. lifted its stake in Evolus by 7.5% in the second quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock worth $316,000 after purchasing an additional 2,383 shares during the last quarter. Quantbot Technologies LP boosted its position in Evolus by 15.4% during the second quarter. Quantbot Technologies LP now owns 29,731 shares of the company’s stock valued at $274,000 after buying an additional 3,971 shares during the period. Finally, Quadrature Capital Ltd boosted its position in Evolus by 29.9% during the fourth quarter. Quadrature Capital Ltd now owns 18,095 shares of the company’s stock valued at $120,000 after buying an additional 4,168 shares during the period. 90.69% of the stock is owned by hedge funds and other institutional investors.
Evolus Company Profile
Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.
The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.
Featured Stories
- Five stocks we like better than Evolus
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
